Pliant Therapeutics (NASDAQ: PLRX) reports 2026 director, pay and auditor votes
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Pliant Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the April 15, 2026 record date, 61,914,664 shares of common stock were outstanding and entitled to vote.
Stockholders elected Bernard Coulie, M.D., Ph.D., MBA, Gayle Crowell, and Steve Krognes, MBA as Class III directors to serve until the 2029 annual meeting. They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares entitled to vote: 61,914,664 shares
Votes for Bernard Coulie: 18,824,540 votes
Votes for Gayle Crowell: 18,186,914 votes
+3 more
6 metrics
Shares entitled to vote
61,914,664 shares
Common stock outstanding as of April 15, 2026 record date
Votes for Bernard Coulie
18,824,540 votes
Election as Class III director, Proposal 1
Votes for Gayle Crowell
18,186,914 votes
Election as Class III director, Proposal 1
Votes for Steve Krognes
19,299,728 votes
Election as Class III director, Proposal 1
Say-on-pay votes for
15,282,788 votes
Non-binding advisory approval of executive compensation, Proposal 2
Auditor ratification votes for
41,710,604 votes
Ratification of Deloitte & Touche LLP, Proposal 3
Key Terms
broker non-votes, non-binding advisory vote, independent registered public accounting firm, record date, +1 more
5 terms
broker non-votes financial
"The broker non-votes for Proposal No. 1 totaled 11,895,135 shares of common stock."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding advisory vote financial
"to approve, by non-binding advisory vote, the resolution approving the compensation of the Company’s named executive officers"
A non-binding advisory vote is a shareholder vote that expresses investors’ opinion on a proposal (such as executive pay, corporate policy, or governance practices) but does not legally force the company to act. Think of it like a customer survey: it signals whether owners approve or disapprove and can pressure boards and managers to change course, so investors watch the result as an indicator of governance risk and potential future shifts in company strategy or leadership.
independent registered public accounting firm financial
"to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
record date financial
"As of April 15, 2026, the record date for the Annual Meeting, there were 61,914,664 shares"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
Class III directors financial
"to elect Bernard Coulie, M.D., Ph.D., MBA, Gayle Crowell, and Steve Krognes, MBA, as Class III directors"
Class III directors are members of a company’s board assigned to one of several staggered term groups, so only that class faces election in a particular year while other classes stay in place. For investors this affects corporate control and takeover risk because staggered elections make it slower and harder for an outside group to replace a majority of directors quickly—think of it as a rotating schedule for board seats that provides continuity but can also entrench existing leadership.
FAQ
What did Pliant Therapeutics (PLRX) stockholders vote on at the 2026 annual meeting?
Stockholders voted on three items: electing three Class III directors, approving executive compensation on a non-binding advisory basis, and ratifying Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Were Pliant Therapeutics (PLRX) director nominees elected at the 2026 annual meeting?
Yes. Stockholders elected Bernard Coulie, M.D., Ph.D., MBA, Gayle Crowell, and Steve Krognes, MBA as Class III directors to serve until the 2029 annual meeting and until their successors are duly elected and qualified, or earlier death, resignation, or removal.
How did Pliant Therapeutics (PLRX) stockholders vote on executive compensation in 2026?
Stockholders approved the non-binding advisory resolution on named executive officer compensation, with 15,282,788 votes for, 14,572,455 against, and 776,605 abstentions, plus 11,895,135 broker non-votes recorded on this say-on-pay proposal at the 2026 annual meeting.
Which audit firm did Pliant Therapeutics (PLRX) stockholders ratify for fiscal 2026?
Stockholders ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 41,710,604 votes for, 747,140 against, and 69,239 abstentions, and no broker non-votes recorded on this ratification proposal.
What were broker non-votes on Pliant Therapeutics (PLRX) 2026 meeting proposals?
Broker non-votes totaled 11,895,135 shares for both the director election proposal and the say-on-pay proposal. There were no broker non-votes recorded on the ratification of Deloitte & Touche LLP as the independent registered public accounting firm.